Effects of Alirocumab Combined with Metoprolol on Cardiac Function and Cardiovascular Adverse Events in Patients with Acute Myocardial Infarction after PCI
Objective:To observe and explore the effect of Alirocumab and Metoprolol in patients with acute myocardial infarction(AMI)after percutaneous coronary intervention(PCI)and its preventive effect on cardiovascular adverse events.Method:A total of 85 patients with AMI who underwent PCI in Department of Cardiology Ⅱ,Jiamusi Central Hospital from January 2021 to November 2022 were retrospectively selected and divided into two groups according to different postoperative treatment methods.The control group(n=43)was treated with Metoprolol after PCI,and the combined group(n=42)was treated with Alirocumab combined with Metoprolol after PCI.The recovery effect of cardiac function in two groups were evaluated.The expression levels of C reactive protein(CRP),myeloperoxidase(MPO)and brain natriuretic peptide(BNP)were compared between the two groups before and after treatment.The occurrence of cardiovascular adverse events in the two groups were observed.Result:The excellent and good rate of cardiac function recovery in the combined group was 90.48%,compared with 69.77%in the control group,the difference was statistically significant(P＜0.05).The expression levels of CRP,MPO and BNP in both groups after treatment were lower than those before treatment,and those in the combined group were lower than those in the control group after treatment,the differences were statistically significant(P＜0.05).The total incidence of cardiovascular adverse events in combined group was lower than that in control group,the difference was statistically significant(P＜0.05).Conclusion:The clinical efficacy of Alirocumab combined with Metoprolol in patients with AMI after PCI is better,which is beneficial to the recovery of cardiac function and reduces cardiovascular adverse events,which may be related to the down-regulation of CRP,MPO and BNP levels.
万方数据
维普
